{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Xu Y"],"pubmed_abstract":["<h4>Background</h4><i>APOE</i> -ρ.4 is the strongest genetic risk factor for Alzheimer's disease (AD), and plasma phosphorylated tau217 (P-tau217) is a highly sensitive and specific biomarker for AD pathology. Their combined utility to predict cognitive decline before onset of AD has not been systematically evaluated.<h4>Methods</h4>Using longitudinal data from multiple cohorts, we evaluated plasma P-tau217 as a predictor of when cognitive impairment occurs in AD. P-tau217 concentrations were analyzed as continuous and binary variables using cohort-specific biomarker positivity thresholds. Association of plasma P-tau217 with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by <i>APOE</i> genotype. Adjusted survival curves and re"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2026.02.06.26345774"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12919147"],"repository":["biostudies-literature"],"pubmed_title":["Predictive Value of Plasma P-tau217 and &lt;i&gt;APOE&lt;/i&gt; Genotype for Preclinical Cognitive Decline in Alzheimer's Disease."],"pmcid":["PMC12919147"],"pubmed_authors":["Petersen M","Mejia DR","Reyes RER","Wilson R","Mayeux R","Gu Y","O'Bryant S","Medrano M","Brickman AM","Reyes-Dumeyer D","Johnson S","Manly JJ","Engelman CD","Gunasekaran TI","Bennett DA","Sanchez D","Honig L","Piriz A","Lantigua RA","Asthana S","Xu Y","Vardarajan BN"],"additional_accession":[]},"is_claimable":false,"name":"Predictive Value of Plasma P-tau217 and &lt;i&gt;APOE&lt;/i&gt; Genotype for Preclinical Cognitive Decline in Alzheimer's Disease.","description":"<h4>Background</h4><i>APOE</i> -ρ.4 is the strongest genetic risk factor for Alzheimer's disease (AD), and plasma phosphorylated tau217 (P-tau217) is a highly sensitive and specific biomarker for AD pathology. Their combined utility to predict cognitive decline before onset of AD has not been systematically evaluated.<h4>Methods</h4>Using longitudinal data from multiple cohorts, we evaluated plasma P-tau217 as a predictor of when cognitive impairment occurs in AD. P-tau217 concentrations were analyzed as continuous and binary variables using cohort-specific biomarker positivity thresholds. Association of plasma P-tau217 with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by <i>APOE</i> genotype. Adjusted survival curves and re","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-12T03:14:53.452Z","creation":"2026-07-12T03:11:15.578Z"},"accession":"S-EPMC12919147","cross_references":{"pubmed":["41728301"],"doi":["10.64898/2026.02.06.26345774"]}}